Price
Financials
Standalone, Rs crore| Mar 2006 | Mar 2007 | Mar 2008 | Mar 2009 | Mar 2010 | Mar 2011 | |
|---|---|---|---|---|---|---|
| Sales | 29.86 | 36.55 | 28.61 | 38.47 | 36.82 | 30.04 |
| Expenses | 23.59 | 29.67 | 29.55 | 30.18 | 29.97 | 26.31 |
| Operating Profit | 6.27 | 6.88 | -0.94 | 8.29 | 6.85 | 3.73 |
| OPM % | 21.00% | 18.82% | -3.29% | 21.55% | 18.60% | 12.42% |
| Other Income | 0.10 | 0.20 | -3.37 | -2.24 | 0.21 | 0.28 |
| Interest | 1.25 | 1.81 | 2.10 | 3.60 | 2.88 | 3.14 |
| Depreciation | 2.44 | 2.57 | 2.77 | 2.80 | 2.84 | 3.07 |
| Profit before tax | 2.68 | 2.70 | -9.18 | -0.35 | 1.34 | -2.20 |
| Tax % | 35.82% | 39.26% | -36.49% | 111.43% | 23.88% | -5.45% |
| Net Profit | 1.72 | 1.64 | -5.83 | -0.74 | 1.02 | -2.08 |
| EPS in Rs | ||||||
| Dividend Payout % | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| 10 Years | 5 Years | 3 Years | TTM | 1 Year | Last Year | |
|---|---|---|---|---|---|---|
| Compounded Sales Growth | % | 0% | 2% | -18% | ||
| Compounded Profit Growth | % | % | -3% | -300% | ||
| Stock Price CAGR | % | % | % | % | ||
| Return on Equity | % | 0% | 1% | -15% |
| Mar 2006 | Mar 2007 | Mar 2008 | Mar 2009 | Mar 2010 | Mar 2011 | |
|---|---|---|---|---|---|---|
| Equity Capital | 7.94 | 7.94 | 7.94 | 7.94 | 7.94 | 7.94 |
| Reserves | 10.49 | 12.13 | 6.30 | 5.25 | 6.39 | 4.31 |
| Borrowings | 21.41 | 19.68 | 28.91 | 28.38 | 31.30 | 36.74 |
| Other Liabilities | 6.10 | 10.13 | 8.97 | 11.47 | 8.06 | 6.62 |
| Total Liabilities | 45.94 | 49.88 | 52.12 | 53.04 | 53.69 | 55.61 |
| Fixed Assets | 27.30 | 27.79 | 26.21 | 24.13 | 24.55 | 23.41 |
| CWIP | 0.00 | 0.00 | 0.11 | 0.09 | 0.54 | 1.21 |
| Investments | 0.12 | 0.04 | 0.04 | 0.04 | 0.14 | 0.14 |
| Other Assets | 18.52 | 22.05 | 25.76 | 28.78 | 28.46 | 30.85 |
| Total Assets | 45.94 | 49.88 | 52.12 | 53.04 | 53.69 | 55.61 |
| Mar 2006 | Mar 2007 | Mar 2008 | Mar 2009 | Mar 2010 | Mar 2011 | |
|---|---|---|---|---|---|---|
| Cash from Operating Activity | -0.57 | 5.07 | -4.71 | 3.81 | 7.45 | -0.93 |
| Cash from Investing Activity | -5.62 | -3.27 | -1.17 | -0.72 | -3.82 | -2.63 |
| Cash from Financing Activity | 6.11 | -1.72 | 7.10 | -4.12 | -1.10 | 2.70 |
| Net Cash Flow | -0.08 | 0.08 | 1.22 | -1.03 | 2.53 | -0.86 |
| Free Cash Flow | -6.07 | 1.80 | -5.88 | 3.09 | 3.72 | -3.56 |
| CFO/OP | -8% | 74% | 501% | 47% | 115% | -20% |
| Mar 2006 | Mar 2007 | Mar 2008 | Mar 2009 | Mar 2010 | Mar 2011 | |
|---|---|---|---|---|---|---|
| Debtor Days | 68.09 | 40.24 | 69.15 | 83.49 | 62.75 | 46.29 |
| Inventory Days | 316.06 | 345.49 | 248.07 | 256.28 | 233.19 | 360.14 |
| Days Payable | 120.00 | 137.70 | 142.47 | 179.57 | 129.62 | 118.73 |
| Cash Conversion Cycle | 264.15 | 248.04 | 174.74 | 160.20 | 166.33 | 287.70 |
| Working Capital Days | 158.30 | 130.42 | 172.61 | 147.54 | 164.36 | 256.86 |
| ROCE % | 11.36% | -7.60% | 14.09% | 9.68% | 2.07% |
Fundamentals
Market Cap₹ Cr.
Current Price₹ 19.8
Book Value₹
ROCE2.07 %
ROE-15.4 %
Dividend Yield0.00 %
Face Value₹ 10.0
Compounded Sales Growth (TTM)-18%
Compounded Profit Growth (TTM)-300%
Standalone figures.
Profitability
Operating margin (excl. other income)18.82%
Operating margin (incl. other income)19.37%
EBITDA margin19.37%
Pre-tax margin7.39%
Net profit margin4.49%
ROE8.52%
ROCE11.33%
ROA3.42%
ROIC (approx.)6.95%
Tax rate39.26%
Other income / net worth1.00%
Growth
Sales growth (latest year)22.40%
Profit growth (latest year)-4.65%
Per share
EPS (TTM)Rs 2.06
EPS (latest year)Rs 2.06
Book value per shareRs 25.26
Sales per shareRs 46.01
Cash flow per shareRs 6.38
Free cash flow per shareRs -4.48
Efficiency
Asset turnover0.73x
Fixed asset turnover1.32x
Inventory turnover1.40x
Inventory days261 days
Debtor days40 days
Debtors turnover9.07x
Creditor days119 days
Cash conversion cycle288 days
Working capital days257 days
Leverage
Total debtRs 20 Cr
Cash and bankRs 0 Cr
Net debtRs 19 Cr
Debt to equity0.98x
Net debt / EBITDA2.73x
Interest coverage2.49x
Owners' fund to total sources40.24%
Debt to assets39.45%
Cash flow
Cash from Operating Activity (latest year)Rs 5 Cr
Cash from Investing Activity (latest year)Rs -3 Cr
Cash from Financing Activity (latest year)Rs -2 Cr
Net Cash Flow (latest year)Rs 0 Cr
Free cash flow (latest year)Rs -4 Cr
FCFE (approx.: FCF + change in debt)Rs -5 Cr
Sales to cash flow7.21x
Statement figures
Net sales (TTM)Rs 37 Cr
Net sales (latest year)Rs 37 Cr
Operating profit excl. other income (latest year)Rs 7 Cr
Other income (TTM)Rs 0 Cr
EBITDA (TTM)Rs 7 Cr
PBDT (TTM)Rs 5 Cr
Profit before tax (TTM)Rs 3 Cr
Tax (latest year)Rs 1 Cr
Net profit (TTM)Rs 2 Cr
Net profit (latest year)Rs 2 Cr
Depreciation (TTM)Rs 3 Cr
Interest (TTM)Rs 2 Cr
Cost of goods sold (latest year)Rs 21 Cr
Total expenditure (latest year)Rs 30 Cr
Total income (latest year)Rs 37 Cr
Share capitalRs 8 Cr
ReservesRs 12 Cr
Shareholders' fundsRs 20 Cr
Total assetsRs 50 Cr
Net blockRs 28 Cr
InvestmentsRs 0 Cr
ReceivablesRs 4 Cr
InventoryRs 15 Cr
Other liabilitiesRs 10 Cr
Shares outstanding (crore)0.79
Computed by MarketFriction from the standalone statements. Returns use average balances.
Not enough history to build valuation bands (needs two years of profits and prices).
Not enough price history.
Red flags
F-score 6 of 8No red flags in the latest statements and filings.
Checks on the latest reported years: cash vs profit, accruals, receivables and inventory vs sales, dilution, debt, interest cover, equity, other income, losses, and auditor, top-management, insolvency and regulator filings in the last 12 months. A flag asks for an explanation; it is not a verdict.
Latest quarter
No quarterly results published.
Activity
Compare| Company | Mcap (Cr) | P/E | ROCE |
|---|---|---|---|
| Sun Pharmaceutical Industries Ltd | 447,476 | 35.4 | 20.5 % |
| Divis Laboratories Ltd | 250,363 | 84.0 | 22.0 % |
| Torrent Pharmaceuticals Ltd | 186,152 | 83.4 | 15.2 % |
| Zydus Lifesciences Ltd | 119,750 | 24.6 | 21.1 % |
| Cipla Ltd | 111,430 | 31.1 | 15.5 % |
| Laurus Labs Ltd | 106,928 | 97.8 | 17.8 % |
| Mankind Pharma Ltd | 105,120 | 49.3 | 13.5 % |
| Dr Reddys Laboratories Ltd | 104,494 | 32.4 | 13.0 % |
| Aurobindo Pharma Ltd | 97,682 | 25.8 | 12.9 % |
| Lupin Ltd | 93,840 | 15.8 | 29.9 % |
| Glenmark Pharmaceuticals Ltd | 68,905 | 22.1 | 39.8 % |
| Alkem Laboratories Ltd | 62,772 | 27.6 | 21.2 % |
| Biocon Ltd | 61,439 | 84.5 | 3.61 % |
| Abbott India Ltd | 57,949 | 35.9 | 44.8 % |
| Gland Pharma Ltd | 49,333 | 43.1 | 15.1 % |
No bulk or block deals on record.
No corporate actions on record.
No announcements in our files yet.
Company filings to NSE, newest first. Routine notices (trading window, newspaper copies) are left out. Click a row for the filing.
No short selling reported to NSE in our files.
Short sales disclosed by brokers to NSE, by trade date. Collected since late September 2026.
Not on any NSE surveillance list in the latest file.
Quick answers
What is the market cap of Tonira Pharma Ltd(merged)?
Tonira Pharma Ltd(merged) (530155) has a market capitalisation of Rs Cr. at the close.